MDM2 as a cancer therapeutic target - Editorial

被引：0
|
作者：
Zhang, RW [1 ]
机构：
[1] Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA
来源：
CURRENT CANCER DRUG TARGETS | 2005年 / 5卷 / 01期
关键词：
D O I：
10.2174/1568009053332609
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1 / 2
页数：2
相关论文
共 50 条
  • [31] MIR-10A AS A THERAPEUTIC TARGET AND PREDICTIVE BIOMARKER FOR MDM2 INHIBITION IN ACUTE MYELOID LEUKEMIA
    Molloy, Tim
    Ma, David
    Roellig, Christoph
    Stoelzel, Friedrich
    Tursky, Melinda
    Vu, Thi Thanh
    Wang, Kristy
    [J]. EXPERIMENTAL HEMATOLOGY, 2021, 100 : S91 - S91
  • [32] MDM2 as MYCN transcriptional target:: Implications for neuroblastoma pathogenesis
    Slack, A
    Lozano, G
    Shohet, JM
    [J]. CANCER LETTERS, 2005, 228 (1-2) : 21 - 27
  • [33] Mammalian Numb is a target protein of Mdm2, ubiquitin ligase
    Yogosawa, S
    Miyauchi, Y
    Honda, R
    Tanaka, H
    Yasuda, H
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 302 (04) : 869 - 872
  • [34] Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
    Carvajal, Luis A.
    Ben Neriah, Daniela
    Senecal, Adrien
    Benard, Lumie
    Thiruthuvanathan, Victor
    Yatsenko, Tatyana
    Narayanagari, Swathi-Rao
    Wheat, Justin C.
    Todorova, Tihomira I.
    Mitchell, Kelly
    Kenworthy, Charles
    Guerlavais, Vincent
    Annis, D. Allen
    Bartholdy, Boris
    Will, Britta
    Anampa, Jesus D.
    Mantzaris, Ioannis
    Aivado, Manuel
    Singer, Robert H.
    Coleman, Robert A.
    Verma, Amit
    Steidl, Ulrich
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (436)
  • [35] Therapeutic considerations for Mdm2: not just a one trick pony
    Lehman, Jason A.
    Eitel, Jacob A.
    Batuello, Christopher N.
    Mayo, Lindsey D.
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (11) : 1309 - 1321
  • [36] MDM2 and PARP as therapeutic targets in acute myeloid leukemia
    Zeuner, S.
    Shah, V
    Haehnel, P. S.
    Szybinski, J.
    Strand, D.
    Theobald, M.
    Kuehn, M. W. M.
    Kindler, T.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 77 - 78
  • [37] MDM2 antagonists - a therapeutic approach for patients with hepatocellular carcinoma?
    Mahdi, A.
    Lunec, J.
    Reeves, H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 61 : S44 - S44
  • [38] MDM2 as a target for ellagic acid-mediated suppression of prostate cancer cellsin vitro
    Saleem, Yasir I. Mohammed
    Selim, Mustafa, I
    [J]. ONCOLOGY REPORTS, 2020, 44 (03) : 1255 - 1265
  • [39] MDM2, an introduction
    Iwakuma, T
    Lozano, G
    [J]. MOLECULAR CANCER RESEARCH, 2003, 1 (14) : 993 - 1000
  • [40] MDM2 and prognosis
    Onel, K
    Cordon-Cardo, C
    [J]. MOLECULAR CANCER RESEARCH, 2004, 2 (01) : 1 - 8
12345